Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

How Genomic Medicine Helps in Proactive Detection and Treatment


Affiliations
1 IISC, Bangalore, India
     

   Subscribe/Renew Journal


Great advances have been made in understanding the genetic profile of human beings. Such genetic information is opening up new and exciting branch of genetic medicine. This has great promise in predictive healthcare, pre-emptive treatment, effective and precision treatment for existing illnesses and more importantly for highly personalised healthcare.

This article explains the potential with a case study.


Subscription Login to verify subscription
User
Notifications
Font Size


  • Hamid Reza Mozaffari, FetemehRezaei, RoohollahSharifi, and S. GhasemMirbahari, “SevenYear Follow-Up of Peutz-Jeghers Syndrome,” Case Reports in Dentistry, vol. 2016, Article ID 6052181, 3 pages, 2016. doi:10.1155/2016/6052181
  • I. R. Schreibman, M. Baker, C. Amos, and T. J. McGarrity, “The hamartomatous polyposis syndromes: a clinical and molecular review,” American Journal of Gastroenterology, vol. 100, no. 2, pp. 476–490, 2005.
  • http://www.dermnetnz.org/systemic/peutz-jeghers.html
  • https://www.nlm.nih.gov/medlineplus/ency/article/ 000244.htm
  • McGarrity TJ, Amos CI, Frazier ML, et al. PeutzJeghers Syndrome. 2001 Feb 23 [Updated 2013 Jul 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: http:// www.ncbi.nlm.nih.gov/books/NBK1266/
  • https://ghr.nlm.nih.gov/condition/peutz-jegherssyndrome# genes
  • Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC, Westerman AM, Entius MM, GogginsM, Yeo CJ, Kern SE. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene inpancreatic and biliary cancers.Am J Pathol. 1999 Jun;154(6):1835-40.
  • Shaw RJ, Bardeesy N, Manning BD, et al. (2004) The LKB1 tumor suppressor negatively regulates mTORsignaling. Cancer Cell 6(1):91-9
  • Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitorsin cancer therapy. Journal of Hematology & Oncology. 2009;2:45.
  • Zhao R-X, Xu Z-X. Targeting the LKB1 Tumor Suppressor. Current drug targets. 2014;15(1):32-52.
  • Klümpen HJ, Queiroz KC, Spek CA, et al. (2011) mTOR inhibitor treatment of pancreatic cancer in apatient With Peutz-Jeghers syndrome. J ClinOncol 29(6):e150-3
  • Carretero J, Shimamura T, Rikova K, et al. (2010) Integrative genomic and proteomic analyses identifytargets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17(6):547-59
  • Nishioka Y, Kobayashi K, Sagae S, Sugimura M, Ishioka S, Nagata M, Terasawa K, Tokino T, KudoR. Mutational analysis of STK11 gene in ovarian carcinomas. Jpn J Cancer Res. 1999 Jun;90(6):629-32.

Abstract Views: 283

PDF Views: 0




  • How Genomic Medicine Helps in Proactive Detection and Treatment

Abstract Views: 283  |  PDF Views: 0

Authors

Vidya H. Veldore
IISC, Bangalore, India

Abstract


Great advances have been made in understanding the genetic profile of human beings. Such genetic information is opening up new and exciting branch of genetic medicine. This has great promise in predictive healthcare, pre-emptive treatment, effective and precision treatment for existing illnesses and more importantly for highly personalised healthcare.

This article explains the potential with a case study.


References